TXG
10x Genomics, Inc. · Healthcare · Medical - Healthcare Information Services
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +23.1% · net new positions 0.0% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 113 | +6 | 98.93M | $3.79B | +15 | −8 |
| Q1 2026 | 109 | +3 | 94.02M | $1.99B | +12 | −10 |
| Q4 2025 | 107 | +3 | 97.86M | $1.59B | +4 | — |
| Q3 2025 | 19 | -2 | 71.88M | $839.83M | — | −3 |
| Q2 2025 | 19 | +1 | 64.66M | $748.72M | +2 | −1 |
| Q1 2025 | 15 | 0 | 30.56M | $266.82M | +1 | −1 |
| Q4 2024 | 15 | +1 | 24.83M | $356.61M | +3 | −2 |
| Q3 2024 | 13 | 0 | 22.71M | $512.82M | +1 | −1 |
| Q2 2024 | 13 | — | 21.07M | $409.76M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | ARK Investment Management ✦ | 12.85M | +7.5% | $112.14M | 1.1% | ▲ Add | 4 | SEC ↗ |
| 2 | Millennium Management ✦ | 5.38M | +442.5% | $46.95M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 3 | D. E. Shaw & Co. ✦ | 1.98M | +62.7% | $17.31M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 4 | Geode Capital Management ✦ (passive) | 1.88M | +3.5% | $16.40M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 5 | State Street Global Advisors ✦ (passive) | 1.81M | +2.1% | $15.82M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | Capital World Investors ✦ | 1.45M | +83.1% | $12.68M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | Two Sigma Investments ✦ | 1.43M | +8.0% | $12.44M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 8 | AQR Capital Management ✦ | 1.21M | +134.4% | $10.58M | 0.0% | ▲ Add | 4 | SEC ↗ ×5 |
| 9 | Citadel Advisors ✦ | 1.06M | -47.0% | $9.29M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 10 | Renaissance Technologies ✦ | 689.55K | +78.2% | $6.02M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | Marshall Wace ✦ | 417.45K | +790.8% | $3.64M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 12 | T. Rowe Price ✦ | 251.26K | -85.9% | $2.19M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 13 | Norges Bank ✦ (passive) | 108.56K | +18.5% | $947,729 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 14 | PRIMECAP Management ✦ | 30.00K | -76.5% | $261,900 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 15 | Arrowstreet Capital ✦ | 16.58K | New | $144,752 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Arrowstreet Capital | $144,752 | 0.0% |
Exited
| Gotham Asset Management | $264,066 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 328 holders, 124.40M shares, $2.59B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 1.00K sh · $78,228
Director · 1.22K sh · $100,542
Director · 2.27K sh · $185,391
Director · 1.32K sh · $107,082
Director · 614 sh · $48,820
Director · 292 sh · $22,833
Officer, Director · 2.80K sh · $230,622
Officer, Director · 9.90K sh · $810,071
Officer, Director · 9.30K sh · $752,401
Officer, Director · 2.00K sh · $159,239
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology